Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcitonin.

Stuart L Silverman1

  • 1Department of Medicine and Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. Stuarts@omcresearch.org

Endocrinology and Metabolism Clinics of North America
|April 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Opportunistic Osteoporosis Screening Using Chest Radiographs With Deep Learning in the United States.

Journal of the American College of Radiology : JACR·2025
Same author

Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United States.

JBMR plus·2024
Same author

Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.

Aging clinical and experimental research·2024
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Nasal calcitonin effectively treats postmenopausal osteoporosis and offers pain relief for vertebral fractures. It is a viable option for patients intolerant to bisphosphonates or with renal impairment.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Geriatrics

Background:

  • Calcitonin is FDA-approved for treating postmenopausal osteoporosis, with nasal administration being the preferred route.
  • While safe and well-tolerated, its efficacy in fracture prevention is not established.

Purpose of the Study:

  • To evaluate the efficacy and safety of calcitonin in managing postmenopausal osteoporosis.
  • To compare calcitonin's effectiveness against other osteoporosis treatments and assess its role in specific patient populations.

Main Methods:

  • Review of FDA-approved indications and delivery systems for calcitonin.
  • Comparison of vertebral and hip fracture efficacy with bisphosphonates (alendronate, risedronate) and raloxifene.
  • Assessment of bone mass and turnover effects, and analgesic potential.

Related Experiment Videos

Main Results:

  • Nasal calcitonin is safe and well-tolerated.
  • Vertebral fracture efficacy is less robust than bisphosphonates but similar to raloxifene.
  • No demonstrated reduction in hip fracture risk, though some analyses suggest potential.
  • Calcitonin increases spinal bone mass and reduces bone turnover; may offer analgesic benefits for painful fractures.

Conclusions:

  • Calcitonin is indicated for treating established osteoporosis, particularly in patients with painful vertebral fractures.
  • Consider calcitonin for women who cannot tolerate or do not respond to bisphosphonates, or those with renal impairment.